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Mesenchymal Stem Cells 
Reduce Murine Atherosclerosis 
Development
Vanessa Frodermann1,†, Janine van Duijn1, Melissa van Pel2, Peter J. van Santbrink1, 
Ilze Bot1, Johan Kuiper1 & Saskia C. A. de Jager1,3
Mesenchymal stem cells (MSCs) have regenerative properties, but recently they were also found 
to have immunomodulatory capacities. We therefore investigated whether MSCs could reduce 
atherosclerosis, which is determined by dyslipidaemia and chronic inflammation. We adoptively 
transferred MSCs into low-density lipoprotein-receptor knockout mice and put these on a Western-
type diet to induce atherosclerosis. Initially after treatment, we found higher levels of circulating 
regulatory T cells. In the long-term, overall numbers of effector T cells were reduced by MSC 
treatment. Moreover, MSC-treated mice displayed a significant 33% reduction in circulating 
monocytes and a 77% reduction of serum CCL2 levels. Most strikingly, we found a previously 
unappreciated effect on lipid metabolism. Serum cholesterol was reduced by 33%, due to reduced 
very low-density lipoprotein levels, likely a result of reduced de novo hepatic lipogenesis as 
determined by a reduced expression of Stearoyl-CoA desaturase-1 and lipoprotein lipase. MSCs 
significantly affected lesion development, which was reduced by 33% in the aortic root. These lesions 
contained 56% less macrophages and showed a 61% reduction in T cell numbers. We show here for 
the first time that MSC treatment affects not only inflammatory responses but also significantly 
reduces dyslipidaemia in mice. This makes MSCs a potent candidate for atherosclerosis therapies.
Mesenchymal stem cells (MSCs), also called bone marrow stromal cells or mesenchymal stromal cells, 
are multipotent cells that can give rise to cells of the mesodermal lineage, including adipocytes, osteo-
cytes and myocytes1. They were first identified in the bone marrow, but can be isolated from other tissues 
such as umbilical cord, placenta and adipose tissue2. After isolation, MSCs can be easily expanded with-
out losing their multipotency which renders them an interesting tool for therapeutic strategies1. MSCs 
were initially investigated for their ability to repair injured heart tissue after myocardial infarction3–5. 
They can migrate to sites of tissue damage and inflammation, where they can extravasate, engraft the 
tissues and reduce scar formation4,6–9.
In recent years the immunomodulatory capacity of MSCs has been increasingly appreciated. 
Several studies have investigated the capacity of MSCs to modulate both innate and adaptive immune 
responses2,10–15. For instance, MSCs have been shown to reduce monocyte responses after myocardial 
infarction11 and to skew macrophages to an anti-inflammatory IL-10-producing phenotype11–14. MSCs 
also inhibit the differentiation and maturation of dendritic cells (DCs)15, by reducing the expression 
of co-stimulatory molecules and pro-inflammatory cytokines (TNF-α and IL-12), while increasing the 
production of anti-inflammatory cytokines (TGF-β and IL-10)16,17, which indirectly suppresses T cell 
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proliferation17. However, MSCs can also directly inhibit T cell proliferation16–18, by inducing cell cycle 
arrest in all subsets, resulting in a quiescent state and decreased proliferation19.
Inflammatory processes play a crucial role in all stages of atherosclerosis. Early in the disease pro-
cess, entrapped oxidized low-density lipoprotein (oxLDL) in the vessel wall leads to the activation of 
arterial endothelial cells and an ensuing recruitment of monocytes and T cells20. Upon recruitment, 
monocytes can differentiate to macrophages21. Macrophages can primarily promote T cell responses to 
local antigens, while DCs can activate naïve T cells in response to lesion-derived antigens in draining 
lymph nodes22. DCs are also present within lesions or can arise from blood-derived precursors. Both 
macrophages and DCs express scavenger receptors enabling the uptake of oxLDL and foam cell forma-
tion and toll-like receptors, which mediate activation of the antigen-presenting cells and production of 
pro-inflammatory cytokines. CD4+ T cells are crucially involved in the pathogenesis of atherosclerosis 
and their depletion results in a 70% reduction of lesion size23. The predominant subset in both human 
and murine atherosclerotic lesions is the Th1 subset24,25, which produces a plethora of pro-inflammatory 
cytokines such as IFN-γ . IFN-γ promotes vascular inflammation by enhancing maturation and activa-
tion of antigen-presenting cells, increasing macrophage lipid uptake, reducing collagen production by 
smooth muscle cells, and enhancing expression of endothelial adhesion molecules, which subsequently 
stimulates leukocyte recruitment to the lesions26. The continuous recruitment of further leukocytes to 
atherosclerotic lesions results in a vicious self-maintaining progressive inflammatory cycle. Nonetheless, 
it has been shown that by altering the phenotype of macrophages and DCs, they can become athero-
protective22,27,28. Moreover, regulatory T cells (Tregs) have been clearly established as anti-atherogenic29. 
Tregs produce high amounts of the anti-inflammatory cytokine IL-10 and inhibit ongoing inflammation.
Due to the key role of inflammatory processes in the initiation and progression of atherosclerosis, 
adoptive transfer of MSCs, which have the capacity to modulate and reduce inflammation, may be a ther-
apeutic approach to treat atherosclerosis. Preclinical studies have already shown that adoptively trans-
ferred MSCs are capable of modulating immune responses and they can prevent allograft rejection18,30 
and alleviate autoimmune diseases31–33. Moreover, in a phase II clinical trial, it was found that MSCs 
can reduce graft-versus-host disease34. We now show to our knowledge for the first time that MSCs in 
addition to their immunomodulatory capacity can significantly reduce dyslipidemia, thus establishing 
the multifactorial therapeutic potential of MSCs to inhibit atherogenesis.
Results
MSCs were generated from the bone marrow of male C57BL/6 mice and their phenotype was confirmed 
by flow cytometry analysis. All MSCs expressed Sca-1, CD29, CD44, CD105 and CD106, while CD45, 
CD31 and TER119 were not expressed (Supplementary Fig. 1). To confirm their immunomodulatory 
capacity, MSCs were co-cultured with DCs for three hours at different ratios, and subsequently stimulated 
with LPS. Twenty-four hours after LPS stimulation, we did not observe effects of MSCs on the expression 
of the co-stimulatory molecules CD40, OX40L and CD30L by DCs. The percentage of DCs positive for 
the co-stimulatory molecule CD86 and the negative co-stimulatory molecule PD-L2 increased by 12% 
and 22%, respectively. The mean expression of CD86 per cell was not significantly affected, whereas the 
mean expression of PD-L2 was decreased by 18% at higher MSC to DC ratios. The mean expression 
of the co-stimulatory molecule CD80 on DCs was significantly increased by 34% (Table  1; P < 0.001) 
upon co-culture with MSCs. CD80/CD86 function to induce T cell activation but can also promote Treg 
development, while PD-L2 functions to inhibit T cell activation, indicating that DCs might adopt a more 
tolerogenic phenotype after exposure to MSCs. In line with this, MSCs significantly affected the cytokine 
production of DCs in response to LPS. Pro-inflammatory TNF-α release was reduced by 57% (P < 0.001) 
while anti-inflammatory IL-10 production was increased by 45% (Fig. 1a; P < 0.01).
Since MSCs have been shown to affect T cell responses, we co-cultured MSCs with splenocytes from 
an atherosclerosis-prone LDLr KO mouse in the presence of α CD3/CD28 for 72 hours. MSCs potently 
inhibited T cell proliferation by 99%, as measured by 3H-thymidine incorporation, compared to α CD3/
CD28 stimulated splenocytes in the absence of MSCs. CD4+ T cell proliferation was reduced by 92% and 
CD8+ T cell proliferation by 87%, as measured by Ki-67 expression. Polarization of all CD4+ T cell sub-
sets was inhibited to a similar extent (Th1 and Th2 more than 99% and Tregs by 89%; Fig. 1b). Cytokine 
responses in the splenocyte co-culture indicated similar effects: IL-10 production was not detectable, 
IFN-γ was reduced by 99%, and TNF-α showed a 92% reduction upon the co-incubation with MSCs. 
Co-cultures of isolated CD4+ T cells and MSCs showed comparable, but milder effects: proliferation of 
CD4+ T cells was on average reduced by 80%, the skewing towards specific T cell subsets was reduced by 
an average of 85%, and cytokine production was also almost completely abolished (Supplementary Fig. 2). 
Interestingly, MSC culture supernatant had no effect on T cell proliferation, suggesting that cell-cell 
contact is crucial (Supplementary Fig. 3).
Before determining the effect of MSCs on atherosclerosis, we fluorescently labelled MSCs with CFSE 
and established the fate of these fluorescently labelled MSCs after intravenous injection into LDLr KO mice 
on a cholesterol rich diet (WTD) and determined to which organs they migrated (Supplementary Fig. 4). 
After fifteen minutes, MSCs accumulated primarily in the lungs and then slowly migrated out of the lungs. 
One to three hours after injection, we found that MSCs had migrated to the liver, the heart, the draining 
lymph nodes of the heart and the aorta. Surprisingly, only few MSCs were recovered in the spleen.
www.nature.com/scientificreports/
3Scientific RepoRts | 5:15559 | DOi: 10.1038/srep15559
To test whether MSCs are able to modulate immune responses and thereby atherosclerosis, LDLr 
KO mice were treated with three intravenous injections of MSCs every other day prior to induction of 
atherosclerosis by WTD feeding. One day after the start of WTD, we found a significant 38% drop in 
circulating CD4+ T cells (control: 14.1% versus MSC: 8.7%, P < 0.05). Interestingly, we also observed 
an initial 51% increase in circulating Tregs (control: 9.2% versus MSC: 13.9%, P < 0.001; Fig. 2a). Eight 
weeks after inducing atherosclerosis, no difference in absolute white blood cell counts (data not shown) 
and percentage of circulating and splenic CD4+ T cells was found (Supplementary Fig. 5). A signifi-
cant 18% decrease in splenic effector CD62L−/CD4+ T cells was observed (P < 0.001; Fig.  2b), while 
no effects on T cell subsets could be observed. In the circulation Th1 cells were significantly reduced 
by 44% (P < 0.01) and Tregs were reduced by 10% (P < 0.05). No significant effects of MSC therapy on 
Th2 cells were observed (Fig.  2b). Total CD8+ T cell numbers were not affected by MSC treatment in 
the circulation throughout the entire experiment (Fig. 3a) and were also not affected in the spleen after 
eight weeks of WTD (Supplementary Fig. 5). However, we again found a significant 25% decrease in 
effector CD62L−/CD8+ T cells in the circulation and spleen after eight weeks WTD upon MSC treatment 
(P < 0.05, Fig. 3b). To evaluate the proliferative capacity of T cells after MSC treatment, we isolated sple-
nocytes eight weeks after induction of atherosclerosis by WTD feeding and cultured them in the presence 
of α CD3/CD28. In line with the in vitro data, splenocytes obtained from MSC-treated recipients showed 
a significant 30% decrease in T cell proliferation (P < 0.01, Fig. 3c). Furthermore, MSC treatment also 
significantly reduced circulating monocytes by 33% (P < 0.05), which was directly associated with a 77% 
reduction in serum CCL2 levels (P < 0.01; Fig. 3d), again suggesting a reduced inflammatory status of 
the MSC-treated mice. In line, although levels are just detectable, we observe a significant decrease in 
circulating IFN-γ both at 7 days (P < 0.01) and 8 weeks (P < 0.05) of WTD and a significant increase in 
circulating IL-10 levels (p < 0.05) in MSC treated animals after 8 weeks of WTD (Fig. 4a). Additionally, 
we observed a 20% reduction of IFN-γ (P = 0.05) and a 31% reduction of IL-6 (P < 0.05) in the draining 
lymph nodes of the heart. Moreover, we see a significant 76 % reduction of IFN-γ (P < 0.01) in the liver, 
and a 33% reduction of TNF-α expression (P < 0.05) in white adipose tissue (Fig. 4b).
As atherosclerosis is further determined by dyslipidaemia, we monitored weight and cholesterol lev-
els throughout the entire experiment. Interestingly, although we did not observe a significant effect on 
weight or a direct effect of MSCs on plasma cholesterol levels after adoptive transfer, we found a signif-
icant 33% reduction in serum cholesterol levels in MSC-treated mice after eight weeks WTD (Fig. 5a). 
The decrease in cholesterol level was mainly a result of a decreased very low-density lipoprotein (VLDL) 
level as assessed by fast protein liquid chromatography analysis (P < 0.01; Fig.  5b). We found that the 
expression of hepatic lipoprotein lipase (LPL), which hydrolyses triglycerides into free fatty acids needed 
for VLDL synthesis, was significantly reduced by 34% (P < 0.01; Fig. 5c). In adult liver LPL is expressed 
by macrophages (Kupffer cells), which were not affected in their number as assessed by F4/80 and Clec4f 
expression, as well as CD68 expression (Supplementary Fig. 6). In white adipose tissue LPL regulates fatty 
DCs only ½ MSC per DC 1 MSC per DC 2 MSCs per DC
Percentages
 CD80 95.5 ± 0.3 97.5 ± 0.4 98.2 ± 0.1 98.2 ± 0.1
 CD86 68.1 ± 0.7 73.8 ± 0.3 (***) 76.0 ± 0.1 (***) 76.5 ± 0.1 (***)
 CD40 88.9 ± 0.3 92.1 ± 2.0 90.1 ± 0.8 93.43 ± 0.2
 OX40L 35.5 ± 0.8 47.6 ± 3.7 (*) 43.2 ± 1.1 44.1 ± 0.4
 CD30L 18.2 ± 1.9 17.6 ± 12 19.5 ± 1.2 21.1 ± 1.5
 PD-L2 50.9 ± 0.6 56.5 ± 2.3 61.8 ± 0.9 (**) 62.5 ± 0.15 (**)
MFI
 CD80 12666 ± 118 15568 ± 407 (***) 16351 ± 321 (***) 16961 ± 272 (***)
 CD86 49906 ± 446 55290 ± 957 (***) 52075 ± 55 49102 ± 75
 CD40 12447 ± 177 12065 ± 1148 11825 ± 287 12622 ± 12
 OX40L 7439 ± 78 7655 ± 221 8196 ± 139 8135 ± 91
 CD30L 2943 ± 41 2953 ± 53 2924 ± 32 3018 ± 59
 PD-L2 5469 ± 105 5012 ± 100 4695 ± 211 4534 ± 76 (*)
Table 1.  MSCs only mildly affect co-stimulatory molecule expression of LPS-stimulated DCs. DCs 
were co-cultured with indicated ratios of MSCs for 3 hours prior to addition of 100 ng/mL LPS for 24 hours. 
DC numbers remained constant. Co-stimulatory molecules on DCs, determined as CD11c+MHCII+, 
were determined by flow cytometry. The percentage and mean fluorescence intensity (MFI) is shown. All 
values are expressed as mean ± SEM and representative of two independent experiments done in triplicate. 
*P < 0.05, **P < 0.01, ***P < 0.001.
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acid uptake from triglyceride-rich lipoproteins for storage35. We found no difference in LPL expression in 
white adipose tissue (Supplementary Fig. 6), indicating that the reduction of LPL is specific for the liver.
Furthermore, we found a significant 27% reduction of Sterol regulatory element-binding protein 
(SREBP)-2 (P < 0.05) and a non-significant 18% reduction of SREBP-1c (P = 0.06; Fig.  5d); transcrip-
tion factors activating multiple genes to promote triglyceride and cholesterol synthesis and thereby 
VLDL synthesis. Several genes involved in hepatic de novo lipogenesis, such as acetyl-CoA carboxylase 
1 (ACC1) and fatty acid synthase (FASN) were not affected (Fig. 5e). Also diglyceride acyltransferase 1 
(DGAT1), involved in the last steps of triglyceride synthesis, and microsomal triglyceride transfer protein 
(MTTP), important for lipoprotein assembly, were not affected (Supplementary Fig. 6). However, strik-
ingly, the rate-limiting enzyme in fatty acid synthesis stearoyl-CoA desaturase-1 (Scd1) was significantly 
reduced by 35% (P < 0.01; Fig.  5e). It should be noted that while expression levels are not necessarily 
identical to protein levels, these are predictive for VLDL metabolism and have been shown to correlate 
with atherosclerosis development36,37.
The beneficial effects of MSC treatment both on immune responses and cholesterol metabolism resulted 
in a significant 33% decrease in atherosclerotic lesion size in MSC-treated mice (1.4 × 105 ± 0.2 × 105 μ m), 
compared with control mice (2.1 × 105 ± 0.3 × 105 μ m, P < 0.05; Fig.  6a). Similar trends were observed 
when determining lesion area in all mice as percentage of vessel lumen, while lipid deposition was 
not affected (Supplementary Fig. 7). Additionally, we determined a significant 56% reduction in rela-
tive macrophage positive area of total lesion size (control: 29.4 ± 4.3% vs. MSC: 13.0 ± 2.6%, P < 0.01; 
Fig. 6b) and a 61% reduction of adventitial CD3+ T cells (control: 0.65 ± 0.12 cells per 105 μ m2 vs. MSC: 
0.25 ± 0.09 cells per 105 μ m2, P < 0.01; Fig. 6c), indicating a reduced inflammatory status of the lesions. 
Lesion stability was not affected as the collagen content, determined by Masson’s trichrome staining, 
was not significantly different between the groups (control: 21.7 ± 1.1% vs. MSC: 19.4 ± 2.0%; Fig. 6d). 
Figure 1. MSCs affect innate and adaptive immune responses. (a) DCs were co-cultured with indicated 
ratios of MSCs for 3 hours prior to addition of 100 ng/mL LPS for 24 hours. DCs numbers remained 
constant. Cytokine responses were determined by ELISA. (b) Splenocytes from an LDLr KO mouse were 
co-cultured with indicated ratios of MSCs in the presence of α CD3/CD28 for 72 hours. Proliferation was 
assessed by 3H-thymidine incorporation and Ki-67 expression by flow cytometry. Splenocyte numbers 
remained constant. All values are expressed as mean ± SEM and representative of at least two independent 
experiments done in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001. ND defines not determined.
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Moreover, no difference in fibrous cap size and necrotic core size was observed (Supplementary Fig. 7), 
indicating that overall lesion composition was not affected.
Discussion
Here we show that MSC treatment may be a promising strategy to reduce atherosclerotic lesion devel-
opment. In agreement with previous studies1,16,18,19, we describe that MSCs can reduce the production 
of pro-inflammatory cytokines by DCs and dramatically inhibit T cell proliferation in vitro. We further 
show that adoptive transfer of MSCs into LDLr KO mice results in an overall reduced inflammatory state, 
as measured by reduced circulating IFN-γ and increased IL-10 levels. In addition, we observe reduced 
IL-6 expression in draining lymph nodes of the heart, reduced TNF-α expression in white adipose tissue 
and reduced IFN-γ expression in livers of MSC-treated mice. Moreover, MSC treatment results in an 
initial drop in circulating CD4+ T cell numbers. While this reduction was only observed initially after 
MSC transfer, a significant decrease in effector CD62L−/CD4+ and CD62L−/CD8+ T cells, as well as a 
significant decreased T cell proliferative capacity, was observed after eight weeks WTD in the spleen, 
clearly indicating a reduced differentiation of naïve T cells, which is consistent with effects observed in 
vitro. In agreement, a significant decrease in circulating Th1 cells and in Tregs was observed eight weeks 
after MSC transfer, as well as a significant reduction in adventitial CD3+ T cell numbers. However, 
directly after MSC treatment we observed an initial increase in circulating Tregs. This is in agreement 
with a recent study by Wang et al.38 who found that MSCs increased Tregs and thereby protect from 
atherosclerosis. However, in this study ApoE KO mice were treated multiple times with MSCs and with 
much higher numbers of MSCs (107) compared to our study (0.5 × 106), which ensured a longer increase 
of Tregs compared to our study. Since we observed an overall significant inhibition of T cell differenti-
ation both in vivo and in vitro, we hypothesized that additional processes and cell types are needed for 
the observed increase in Tregs. It has been suggested that MSCs can induce apoptosis of T cells, which 
Figure 2. MSC treatment affects CD4+ T cell responses in vivo. Male LDLr KO mice received three i.v. 
injections of either PBS (control) or 0.5 × 106 MSCs (MSC) and were then fed a Western-type diet (WTD) 
for eight weeks. (a) CD4+ T cells, as well as the percentage of FoxP3+ regulatory T cells (Treg) within CD4+ 
T cells, were measured in the circulation throughout the entire experiment by flow cytometry. (b) After 
eight weeks, effector CD4+ T cells, determined as CD62L− within CD4+ T cells, as well as T cell subsets of 
CD4+ T cells in the circulation and spleen were determined by flow cytometry. All values are expressed as 
mean ± SEM and representative of six mice per group. *P < 0.05, **P < 0.01, ***P < 0.001.
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may explain the initial drop in CD4+ T cells that we observed in vivo, and that these apoptotic T cells 
are cleared by phagocytes, which in turn may induce Tregs39. Therefore in vivo Tregs could initially 
be induced indirectly, while later the overall inhibition of T cell differentiation reduces Treg numbers. 
Additionally, MSC therapy significantly reduced circulating monocytes and serum CCL2 levels, again 
clearly suggesting reduced immune responses. This is in line with a previous study showing reduced 
monocytes after MSC therapy for myocardial infarction11. The reduced monocytes and their reduced 
recruitment to the lesions resulted in a dramatic 56% reduction in lesional macrophages.
Unexpectedly, we found significantly lower plasma cholesterol levels in MSC-treated mice, due to a 
reduction of VLDL levels, which is to our knowledge an effect that was not been previously described 
upon MSC treatment. The effects of MSC therapy on plasma cholesterol levels only emerged around four 
to five weeks after treatment indicating that the effects of MSCs could be rather indirect, e.g. by modula-
tion of other cell types. Previous studies have found a connection between immune cells and cholesterol 
metabolism. For example lymphotoxins, which are expressed by CD4+ T cells and DCs, play a role in 
the homeostasis of these cells and can also contribute to metabolic disease40,41. CD4+ T cell expression 
of LIGHT, another ligand of the lymphotoxin receptor, increases plasma cholesterol levels, again showing 
a direct link between immune cells and cholesterol metabolism40. Furthermore, an increased lifespan of 
DCs42 and the adoptive transfer of mature DCs was found to correlate with decreased serum cholesterol 
levels43. Hence a modulation of immune cells by MSCs could also indirectly affect cholesterol metabo-
lism. Interestingly, we find a significant reduction of LPL expression only in the liver and not in white 
adipose tissue. In the adult liver, LPL is exclusively expressed by the Kupffer cells44. As no difference 
in Kupffer cell markers was found, we can assume that LPL expression is specifically decreased by the 
Kupffer cells themselves. While LPL KO mice develop severe hypertriglyceridemia45,46, liver-specific LPL 
overexpression also results in hypertriglyceridemia47. Moreover, LPL deficiency in macrophages has been 
found to reduce their uptake of VLDL or oxLDL, thereby decreasing atherosclerosis48,49. Interestingly, 
TNF-α has been shown to induce LPL mRNA and activity in livers in several studies47, indicating that 
reduced LPL expression could be a direct result of reduced inflammation, as we see reduced TNF-α in 
white adipose tissue. However, it must me noted that, although levels are very low, we do not observe 
an effect of MSC treatment on circulating TNF-α levels. This suggests that indeed a modulation of 
macrophage function by MSC treatment could have occurred. Wang et al.38 described that foam cell 
formation is inhibited by MSCs, which suggests that MSC can indeed directly modulate macrophage 
function and activation in atherosclerosis. Interestingly, LPL is secreted and results in the breakdown 
of triglycerides into free fatty acids, which could result in less availability of free fatty acids for VLDL 
Figure 3. MSC treatment affects CD8+ T cell and monocyte responses in vivo. (a) CD8+ T cells were 
measured in the circulation throughout the entire experiment by flow cytometry. (b) After eight weeks, 
effector CD8+ T cells, determined as CD62L− within CD8+ T cells, in the circulation and spleen were 
determined by flow cytometry. (c) Splenocytes were isolated and stimulated with α CD3/CD28 for 72 hours. 
Proliferation was assessed by the amount of 3H-thymidine incorporation. Proliferation is normalized for 
proliferation of controls (without stimulation) and expressed as the stimulation index (S.I.). (d) Circulating 
monocytes, determined as CD11bhiLy-6G−, were analyzed by flow cytometry. CCL2 levels in serum were 
determined by ELISA. All values are expressed as mean ± SEM and representative of six mice per group. 
*P < 0.05, **P < 0.01.
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synthesis by hepatocytes. In addition, previous research has found that activated Kupffer cells can express 
mediators that promote VLDL secretion by hepatocytes50, indicating that a reduced activation of Kupffer 
cells in MSC-treated mice could result in reduced VLDL metabolism. However, also the reduced inflam-
matory environment could have directly affected VLDL synthesis. In line with this, TNF-α , which is 
downregulated upon MSC and splenocyte co-culture, has been shown to upregulate SREBP-1c51, thereby 
increasing VLDL synthesis. On the other hand, IL-10 overexpression has been shown to result in reduced 
plasma cholesterol, mostly due to reduced VLDL, in LDLr KO mice52. Overall, our data indicates that 
MSCs reduce VLDL levels by decreasing inflammation in treated mice and thereby affecting hepatocytes 
and Kupffer cells.
Overall MSC therapy was highly effective in reducing both immune responses and improving dyslipi-
demia, the two driving forces behind atherosclerosis, and resulted in a significant 33% reduction in aortic 
root lesion sizes. Future studies will need to show the effect of MSCs on different stages of atherosclero-
sis, but our observations suggest that due to a combined effect on inflammation and plasma cholesterol 
levels a beneficial effect may be anticipated. For example, an increased stability of advanced lesions can 
be expected as IL-10 has been shown to promote lesion stability53,54. The fact that we do not observe an 
effect on lesion stability is directly associated with the early atherosclerotic lesions which contain a low 
amount of vascular smooth muscle cells. Recently, allogeneic MSCs were evaluated for their potential 
to repair ruptured lesions and were shown to increase regeneration of the inner endothelial lining and 
Figure 4. MSC treatment reduces pro-inflammatory cytokine response. (a) Serum IL-6 levels were 
measured by ELISA, while IFNγ , TNFα and IL-10 levels were determined by luminex immunoassay. mRNA 
expression of IL-6, TNF-α , IFN-γ and IL-10 are shown for draining lymph nodes of the heart (hLN), liver 
and white adipose tissue (WAT). Expression is shown relative to the expression of three housekeeping genes 
(SDHA, HPRT and Rpl27). All values are expressed as mean ± SEM. Serum cytokine levels are representative 
of n = 3 pooled samples (7 days), n = 3 control and n = 6 MSC treated (8 weeks) and mRNA cytokine 
expression is representative of all mice. *P < 0.05. **P < 0.01.
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collagen fiber formation in the vessel wall55, implying their potential for the treatment of progressed 
lesions. Furthermore, a modulation of MSCs to enhance their anti-inflammatory capacities and/or their 
lifespan could prove interesting.
The drawback of some studies10,11 assessing the effect of MSCs on inflammation is that they employ 
human MSCs in SCID mice, which lack T and B cells. As these do not have a fully functional immune 
system it is difficult to examine the effect of MSCs on immune responses. Additionally, there have been 
reports that allogeneic MSCs can be rejected by recipient mice10, a caveat for a recent study by Lin et al.56. 
In this study human MSCs were transferred to ApoE KO mice, which increased eNOS in the aorta and 
thereby increased vasodilation in ApoE KO mice, but only resulted in a mild reduction of atherosclero-
sis. For these reasons, we performed an adoptive transfer of MHC-matched mouse MSCs into LDLr KO 
mice to avoid host immune responses to the grafted MSCs and to be able to do the experiment in mice 
with a functional immune system.
To translate our findings to clinical application, our studies could be in the future replicated using 
human MSCs in humanized mouse models for atherosclerosis, which can be humanized in their immune 
system, e.g. by transfer of human hematopoietic stem cells into SCID, NOG or NSG mice57,58. Also, a 
more humanized cholesterol metabolism, such as in the ApoE*3/CETP-Leiden mice59, would enable a 
confirmation of effects observed on VLDL metabolism. Taken together, our study provides evidence that 
a MSC-based treatment strategy has multifactorial therapeutic potential for inhibiting atherogenesis as it 
reduces inflammatory responses but also limits dyslipidaemia.
Materials and Methods
Animals. C57BL/6 and LDLr KO mice were originally obtained from the Jacksons Laboratory, kept 
under standard laboratory conditions, and administered food and water ad libitum. All animal work was 
approved by the Ethics Committee for Animal Experiments of Leiden University and conforms to Dutch 
government guidelines.
Figure 5. MSC treatment reduces VLDL production. (a) Body weight and cholesterol levels were 
monitored throughout the entire experiment. (b) Cholesterol distribution among plasma lipoprotein 
subclasses was determined by FPLC analysis after eight weeks WTD. For FPLC analysis serum of three mice 
was pooled. (c) Liver mRNA expression of lipoprotein lipase (LPL), (d) of SREBP-1c and SREBP-2, and (e) 
of acetyl-CoA carboxylase (Acc1), fatty acid synthase (FASN), stearoyl-CoA desaturase-1 (Scd1) is shown, 
relative to the expression of three housekeeping genes (SDHA, HPRT and Rpl27). All values are expressed as 
mean ± SEM and representative of all mice. *P < 0.05, **P < 0.01, ***P < 0.001.
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DC culture. For DC cultures, bone marrow cells were isolated from the tibias and femurs of 
C57BL/6 mice. The cells were cultured for ten days at 37 °C and 5% CO2 in 10 cm2 petri dishes in 
IMDM supplemented with 10% FCS, 1% penicillin/streptomycin (all obtained from PAA), 1% glutamax 
(Thermo Fisher Scientific) and 20 μ M β -mercaptoethanol (Sigma Aldrich) in the presence of 20 ng/mL 
granulocyte-macrophage colony-stimulating factor (Preprotech). DC purity was assessed by CD11c 
expression (flow cytometry) and routinely found to be above 95%.
MSC isolation, phenotyping and labelling. Bone marrow cells were obtained by flushing femurs 
with washing medium (RPMI supplemented with 2% FCS, penicillin, streptomycin and L-glutamine). 
Next the bone marrow cells were cultured in a 75 cm2 flask containing α MEM (Life Technologies) sup-
plemented with 10% FCS (Greiner Bio-One), 2% penicillin/streptomycin (Life Technologies) and 1% 
L-Glutamine (Life Technologies; MSC medium). Subsequently, plastic adherent MSCs were cultured to 
95% confluency in a fully humidified atmosphere at 37 °C and 5% CO2, harvested using trypsin and 
further expanded until sufficient numbers were obtained.
The MSCs that were used throughout this study were of passage six to eight; for in vivo MSC treat-
ment cells of passage eight were used. MSC were phenotyped using the following antibodies: TER119 
Figure 6. MSC treatment reduces lesion development. (a) Lesion size in the three valve area of the aortic 
root was determined; representative cross-sections stained with Oil-Red-O and hematoxylin are shown. (b) 
Macrophage content was determined by MOMA-2 staining as percentage of total lesion area. (c) Adventitial 
T cell numbers were determined by α CD3 staining. (d) Collagen content was determined by Masson’s 
Trichrome staining as percentage of total lesion area. Values are expressed as mean ± SEM and representative 
of all mice. *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:15559 | DOi: 10.1038/srep15559
(clone TER119), CD31 (clone MEC 13.3), CD45.2 (clone 104), CD90.2 (clone 53-2.1), CD29 (clone 
HMb1-1), Sca-1 (Clone D7), CD105 (clone MJ7/18), CD44 (clone IM7) and CD106 (clone 429). All 
antibodies were obtained from BD Biosciences.
For tracking experiments, MSCs were labelled with 10 μ M Carboxyfluorescein succinimidyl ester 
(CFSE) according to manufacturer’s protocol (Thermo Fisher Scientific). Briefly, MSCs were resuspended 
in prewarmed PBS/0.1% BSA at a concentration of 1 × 106 cells/mL and incubated with dye at 37 °C for 
10 minutes in the dark. Afterwards, the staining was quenched by adding ice-cold media and incubating 
for another 5 minutes on ice, followed by three subsequent washing steps to remove excess CFSE.
Co-cultures. For DC-MSC co-cultures, 1 million DCs were plated in 2 cm2 non-tissue culture treated 
petri dishes with indicated ratios of MSCs for 24 hours in MSC medium. DCs were stimulated with 
100 ng/mL LPS to determine cytokine responses. Three independent experiments were done in triplicate.
For splenocytes-MSC co-cultures, single cell suspensions of spleens from LDLr KO mice were obtained 
by using a 70 μ m cell strainer (VWR International). Red blood cells were lysed with erythrocyte lysis 
buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.2). 2 × 105 splenocytes were added per well 
with indicated amounts of MSCs.
For T cell-MSC co-cultures, CD4+ T cells (> 95% purity) were isolated from splenocytes by using 
the BD IMagTM mouse CD4 T lymphocyte enrichment set according to manufacturer’s protocol (BD 
Biosciences). 1 × 105 T cells were added per well with indicated amounts of MSCs.
Three independent experiments for both splenocytes and T cell-MSC co-cultures were cultured in 
quintuplicates in 96-well round-bottom plates in the presence or absence of α CD3/28 (2 μ g/mL, eBio-
science) for 72 hours in complete RPMI 1640, supplemented with 10% FCS, 100 U/ml penicillin/strep-
tomycin, 2 mM L-glutamine (all obtained from PAA, Germany) and 20 μ m β -mercaptoethanol (Sigma 
Aldrich). Proliferation was measured by Ki-67 expression by flow cytometry or addition of 3H-thymidine 
(0.5 μ Ci/well) for the last 16 hours of culture. The amount of 3H-thymidine incorporation was measured 
using a liquid scintillation analyzer (Tri-Carb 2900R) as the number of disintegrations per minute (dpm). 
T cell subsets were determined by flow cytometry.
We performed two independent experiments with splenocytes and T cell cultures in the presence of 
MSC culture supernatant in quintuplicates, MSC culture supernatant was added in different concentra-
tion of total medium added. MSC supernatant was filtered using a 0.2 μ m filter to remove residual cells 
before use.
Atherosclerosis. Atherosclerosis was induced in 16 weeks old male LDLr KO mice by feeding a 
Western-type diet (WTD) (0.25% cholesterol and 15% cocoa butter; Special Diet Services). 12 Mice per 
group received 3 i.v. injections of PBS or 0.5 million MSCs every other day prior to eight weeks WTD.
Flow Cytometry. Mice were sacrificed and subsequently, blood and spleen were harvested of six mice 
per group. White blood cells were obtained as described above. 300,000 cells per sample were stained 
with the appropriate FACS antibodies. The following antibodies were used: CD11b-FITC (clone M1/70), 
CD11c-PE (clone N418), CD30L-PE (clone RM153), CD4-PerCP (clone RM4–5; BD Biosciences), 
CD40-FITC (clone HM40-3), CD8-PerCP (clone 53-6.7; BD Biosciences), CD80-PE (clone 16-10A1), 
CD86-APC (clone GL1), FoxP3-APC (clone FJK-16s), Gata-3-PE (clone TWAJ), Ki-67-FITC (clone 
SolA15), Ly-6G-APC (clone 1A8; BD Biosciences), MHCII-FITC (clone AF6-120.1), OX40L-PE (clone 
RM124L), PD-L2-APC (clone MIH18), RORγ t-PE (clone AFKJS-9), and T-bet-Alexa Fluor 647 (clone 
eBio4B10). All antibodies were purchased from eBioscience, unless stated otherwise. For intracellular 
staining, cells were fixed and permeabilized according to the manufacturer’s protocol (eBioscience). 
FACS analysis was performed on the FACS Canto II and data were analyzed using FACS Diva software 
(BD Biosciences).
In Vivo Imaging Systems (IVIS). For MSC tracking experiments, 1 × 106 MSCs were stained with 
CFSE and injected intravenously. Ex vivo imaging was performed by placing either whole animals or 
organs in the IVIS Lumina Imaging System (Xenogen) at indicated time points and analyzing fluores-
cence based on the manufacturer’s recommendations. Fluorescence intensity was quantified as photons/
sec/cm2 by Living Image software (Xenogen).
Histological analysis. To determine plaque size, 10 μ m cryosections of the aortic root of all mice 
were stained with Oil-Red-O and haematoxylin (Sigma Aldrich). Corresponding sections were stained 
for collagen fibers using the Masson’s Trichrome staining (Sigma Aldrich) or immunohistochemically 
with antibodies against a macrophage specific antigen (MOMA-2, polyclonal rat IgG2b, 1:1000, Serotec 
Ltd.). Goat anti-rat IgG alkaline phosphatase conjugate (dilution 1:100; Sigma Aldrich) was used as a sec-
ondary antibody and nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as enzyme sub-
strates. To determine the number of adventitial T cells, CD3 staining was performed using anti-mouse 
CD3 (clone SP7, 1:150, ThermoScientific). BrightVision anti-rabbit-HRP was used as secondary anti-
body (Immunologic). The section with the largest lesion and four flanking sections were analyzed for 
lesion size and collagen content, two flanking sections were analyzed for macrophage and T cell content. 
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All images were analyzed using the Leica DM-RE microscope and LeicaQwin software (Leica Imaging 
Systems, UK). The percentage of collagen, macrophages and Oil-Red-O in the lesions was determined 
by dividing the collagen, MOMA-2- or Oil-Red-O positive area by the total lesion surface area. The 
plaque percentage was calculated by dividing plaque size by the total root area (i.e. plaque + lumen size). 
Relative cap area (in %) was calculated by measuring cap size as percentage of total plaque size.
Real-time PCR. mRNA was isolated from the liver, draining lymph nodes of the heart and white adi-
pose tissue of all mice using the guanidium isothiocyanate method and reverse transcribed (RevertAid 
Moloney murine leukemia virus reverse transcriptase). Quantitative gene expression analysis was per-
formed on a 7500 Fast real-time PCR system (Applied Biosystems) using SYBR Green technology. The 
expression was determined relative to the average expression of three housekeeping genes: succinate 
dehydrogenase complex, Subunit A (SDHA), hypoxanthine phosphoribosyltransferase (HPRT), and 60S 
ribosomal protein L27 (Rpl27). For used primer pairs please refer to Supplementary Table 1.
Cytokines. IL-10, TNF-α , IFN-γ in cell culture supernatant were determined by ELISA (BD 
Biosciences), while IL-10, TNF-α , IFN-γ serum levels were determined in 3–6 animals per group by 
luminex immunoassay (eBioscience, procartaplex) according to manufacturer’s protocol. CCL2 and IL-6 
levels in serum were determined in all mice by ELISA (BD Biosciences) according to manufacturer’s 
protocol.
Serum cholesterol levels. During the experiment, mice were weighed and blood samples were 
obtained by tail vein bleeding. Serum concentrations of total cholesterol were determined by enzymatic 
colorimetric assays (Roche Diagnostics). Precipath (standardized serum; Roche Diagnostics) was used as 
internal standard. The distribution of cholesterol over the different lipoproteins in serum was determined 
by fractionation of 30 μ l of serum using a Superose 6 column (3.2 × 300 mm, Smart-System; Pharmacia). 
Total cholesterol content of the effluent was determined as described above.
Statistical analysis. Values are expressed as mean ± SEM and were tested for normal distribution. 
Data of two groups were analyzed with a two-tailed Student’s T-test. Data of three or more samples were 
compared by one-way ANOVA and data of two groups with more than one variable were analyzed by 
two-way ANOVA, both followed by Bonferroni post-testing. Statistical analysis was performed using 
Prism (GraphPad). Probability values of P < 0.05 were considered significant.
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